tbuckley/cabot-search huggingface dataset:
Relapse of Leukemia with Loss of Mismatched HLA Due to Uniparentaldisomy Follwing Haploidentical Hematopoietic Transplantation.
Authors: Yoshiyuki Takahashi, Itzel Bustos, Yoshiki Akatsuka, Hideki Muramatsu, Nobuhiro Nishio, Asahito Hama, Hiroshi Yagasaki, Hiroh Saji, Motohiro Kato, Seishi Ogawa, Seiji Kojima
Journal: Blood (2009)
Comparable Outcomes of Sibling and Unrelated Donors Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
Authors: He Huang, Yi Luo, Jimin Shi, Wanzhuo Xie, Wenjun Wu, Jingsong He, Jie Zhang, Xiujin Ye, Zhen Cai, Maofang Lin
Journal: Blood (2008)
S95 Ambulatory management of pneumothorax: is there a need for a dedicated pleural team-led service?
Authors: A Fawzi, N Maddekar, S Khan, S Bikmalla, W Osman, U Maqsood, M Haris
Journal: Thorax (2016)

<h3>Introduction</h3> Small, asymptomatic pneumothoraces may be managed as outpatients. Several studies show that small-bore catheters and Heimlich valves may be used in the treatment of pneumothoraces. A systematic review of the literature<sup>1</sup> showed successful outpatient management of pneumothorax. Despite good evidence to support ambulatory approach, there has been slow development of this service across the UK. We wished to assess the number of potential primary spontaneous pneumothorax patients that could be managed as outpatients in a large teaching hospital. <h3>Methods</h3> Hospital attendances of pneumothorax at a large teaching hospital between 2012–2015 were reviewed. Type of pneumothorax was characterised: primary spontaneous (PSP), secondary spontaneous (SSP), iatrogenic (IP) and traumatic/post-operative. The data for PSP was then correlated against the data retrieved from the systematic review of outpatient pneumothorax management.<sup>1</sup> <h3>Results</h3> Total number of pneumothorax episodes were 877; PSP 266, SSP 229, IP 41 and traumatic/post-operative 341. Average length of stay (LOS) for all episodes of pneumothorax was 12.39 days. LOS for PSP was 6.9 days. Total number of hospital admissions for PSP (266/3 =) 88.7 patients/year. Extrapolated from systematic review<sup>1</sup>: Successful outpatient PSP management (88.7*78% =) 77.1 patients/year. Potential bed days saved for PSP: (77.1*6.9 =) 532 beds/year. <h3>Conclusions</h3> Studies show both spontaneous and iatrogenic pneumothorax may be managed safely as outpatients. Dedicated pleural services will result in correct stratification of patients requiring appropriate interventions. Ambulatory chest drains could be used and inserted by professionals trained in their use. Advantages to patients: reduced need for hospital admission, greater patient autonomy, improved patient experience, no need to carry chest drain bottle, reduced likelihood of accidental dislodgement of chest drain, reduced time to discharge. Advantages to trust: admission avoidance, early discharge, reduced costs, reduced complications from chest drain insertions, reduced hospital associated complications, optimised patient care with increased patient satisfaction. Although we would not advocate the use of ambulatory pneumothorax devices in trauma patients, there is scope to establish whether they can be used post procedural (e.g. pneumothorax following pacemaker insertion). <h3>Reference</h3> Brims FJ, Maskell NA. Ambulatory treatment in the management of pneumothorax: a systematic review of the literature. <i>Thorax</i> 2013;<b>68</b>(7):664–9.
FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma
Authors: Julia A. Beaver, Marc R. Theoret, Sirisha Mushti, Kun He, Meredith Libeg, Kirsten Goldberg, Rajeshwari Sridhara, Amy E. McKee, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research (2017)

Abstract On November 23, 2015, the FDA approved nivolumab (OPDIVO; Bristol-Myers Squibb) as a single agent for the first-line treatment of patients with BRAFV600 wild-type, unresectable or metastatic melanoma. An international, double-blind, randomized (1:1) trial conducted outside of the United States allocated 418 patients to receive nivolumab 3 mg/kg intravenously every 2 weeks (n = 210) or dacarbazine 1,000 mg/m2 intravenously every 3 weeks (n = 208). Patients with disease progression who met protocol-specified criteria (∼25% of each trial arm) were permitted to continue with the assigned treatment in a blinded fashion until further disease progression is documented. Overall survival was statistically significantly improved in the nivolumab arm compared with the dacarbazine arm [hazard ratio (HR), 0.42; 95% confidence interval (CI), 0.30–0.60; P &amp;lt; 0.0001]. Progression-free survival was also statistically significantly improved in the nivolumab arm (HR, 0.43; 95% CI, 0.34–0.56; P &amp;lt; 0.0001). The most common adverse reactions (≥20%) of nivolumab were fatigue, diarrhea, constipation, nausea, musculoskeletal pain, rash, and pruritus. Nivolumab demonstrated a favorable benefit–risk profile compared with dacarbazine, supporting regular approval; however, it remains unclear whether treatment beyond disease progression contributes to the overall clinical benefit of nivolumab. Clin Cancer Res; 23(14); 3479–83. ©2017 AACR.
P2.06-038 An RCT of the Detection of Autoantibodies to Tumor Antigens in Lung Cancer Using the EarlyCDT-Lung Test in Scotland (ECLS) in 12 208 Study Subjects
Authors: Frank Sullivan, Alistair Dorward, Frances Mair, Stuart Schembri, Kavita Vedhara, Denise Kendrick, Shaun Treweek, Colin Mccowan, Alex Mcconnachie, Mike Sproule, Andy Briggs, Lewis Ritchie, Robert Milroy, Tom Taylor, Roberta Littleford, David Brewster
Journal: Journal of Thoracic Oncology (2017)
P77 Experience of a joint palliative and respiratory clinic on niv treatment initiation in motor neurone disease
Authors: T Burden, C Davis, E Johnstone, J Spence, D Shrikrishna
Journal: Thorax (2016)

<h3>Introduction</h3> Signs and symptoms of ventilatory failure are a proxy for disease progression in Motor Neurone Disease (MND). Recent National Institute for Health and Clinical Excellence (NICE) guidance for MND recommends early referral to specialist palliative care (NICE, 2016) and this may help inform patient decisions around the initiation of non-invasive ventilation (NIV) A service evaluation was conducted on a new joint palliative and respiratory clinic to determine access to specialist palliative care and the initiation of NIV in MND patients. <h3>Methodology</h3> The joint palliative care and respiratory clinic began in September 2015, at Musgrove Park hospital, Taunton and all patients with MND were included. Electronic records were retrospectively accessed, both from the acute hospital electronic document system (EPRO) and also the palliative care database (Crosscare). The joint clinic group were compared with patients discussed in the local MND multi-disciplinary team meeting prior to initiation of the joint clinic, who had respiratory symptoms (standard care group). <h3>Results</h3> Data was collected in 35 patients with MND. Of these, 9 did not have any respiratory symptoms and were excluded. The joint clinic group (N = 11), included 5 women (45%), mean age 67.9 (SD 8.9); in the standard care group (N = 15) there were 7 (47%) women, mean age 69.2 (7.6) years. Eighty percent of patients receiving standard care were referred to palliative care compared to 100% in the joint clinic. In the standard care group, 12 (80%) of patients were initiated on NIV compared to 5 (45%) in the joint clinic group. There were only 3 unplanned admissions in both groups and the location of patient deaths were not different. <h3>Conclusion</h3> Attending the joint clinic appeared to improve access to palliative care services. Furthermore, patients with MND may benefit from combined palliative and respiratory care input in a joint clinic when making decisions around the initiation of NIV. Further work is needed to evaluate the role of these clinics in informing patient choice for the management of ventilatory failure in this condition. <h3>Reference</h3> National Institute for Health and Care Excellence. Motor Neurone Disease: assessment and management. https://www.nice.org.uk/guidance/ng42?unlid=3630474112016629201321 (accessed July 2016).
The Novel Triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO) Induces Apoptosis of Human Diffuse Large B-Cell Lymphoma Cells (DLCL) through a Peroxisome Proliferator-Activated Receptor γ (PPARγ) Independent Pathway Which Is Enhanced by NFκB Inhibition.
Authors: Denise Ray, Kimberly Morse, Shannon Hilchey, Tatiana Garcia, Raymond Felgar, Sanjay Maggirwar, Richard Phipps, Steven H. Bernstein
Journal: Blood (2005)
P3.03-015 BAP1 is Inactivated by Copy Number Loss, Mutation, and/or Loss of Expression in More Than 70% Malignant Peritoneal Mesotheliomas
Authors: Noémie Leblay, Frédéric Leprêtre, Nolwenn Le Stang, Amandine Gautier-Stein, Laurent Villeneuve, Sylvie Isaac, Denis Maillet, Françoise Galateau-Sallé, Céline Villenet, Shéhérazade Sebda, Graham Byrnes, James Mckay, Martin Figeac, Olivier Glehen, François-Noël Gilly, Matthieu Foll, Lynnette Fernandez-Cuesta, Marie Brevet
Journal: Journal of Thoracic Oncology (2017)
Looking Toward the Future With You
Authors: S. Andrew Josephson
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
P3.02c-064 Higher PD-L1 Expression Correlates with Solid and High Grade Lung Adenocarcinomas: Implications for Immunotherapy Selection
Authors: Brandon Driver, Ross Miller, Tara Miller, Michael Deavers, Blythe Gorman, Dina Mody, Yimin Ge, Roberto Barrios, Eric Bernicker, Min Kim, Philip Cagle
Journal: Journal of Thoracic Oncology (2017)
An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion
Authors: Rami S Komrokji, Guillermo Garcia-Manero, Lionel Ades, Abderrahmane Laadem, Bond Vo, Thomas Prebet, Aspasia Stamatoullas, Thomas Boyd, Jacques Delaunay, David P. Steensma, Mikkael A. Sekeres, Odile Beyne-Rauzy, Jun Zou, Kenneth Attie, Matthew L. Sherman, Pierre Fenaux, Alan F. List
Journal: Blood (2014)
Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response
Authors: Cornelis A.M. van Bergen, Simone A.P. van Luxemburg-Heijs, Liesbeth C. de Wreede, Matthijs Eefting, Peter A. von dem Borne, Peter van Balen, Mirjam H.M. Heemskerk, Arend Mulder, Fransiscus H.J. Claas, Marcelo A. Navarrete, Wilhelmina M. Honders, Caroline E. Rutten, Hendrik Veelken, Inge Jedema, Constantijn J.M. Halkes, Marieke Griffioen, J.H. Frederik Falkenburg
Journal: Journal of Clinical Investigation (2017)

Patients with leukemia who receive a T cell-depleted allogeneic stem cell graft followed by postponed donor lymphocyte infusion (DLI) can experience graft-versus-leukemia (GVL) reactivity, with a lower risk of graft-versus-host disease (GVHD). Here, we have investigated the magnitude, diversity, and specificity of alloreactive CD8 T cells in patients who developed GVL reactivity after DLI in the absence or presence of GVHD. We observed a lower magnitude and diversity of CD8 T cells for minor histocompatibility antigens (MiHAs) in patients with selective GVL reactivity without GVHD. Furthermore, we demonstrated that MiHA-specific T cell clones from patients with selective GVL reactivity showed lower reactivity against nonhematopoietic cells, even when pretreated with inflammatory cytokines. Expression analysis of MiHA-encoding genes showed that similar types of antigens were recognized in both patient groups, but in patients who developed GVHD, T cell reactivity was skewed to target broadly expressed MiHAs. As an inflammatory environment can render nonhematopoietic cells susceptible to T cell recognition, prevention of such circumstances favors induction of selective GVL reactivity without development of GVHD.
Inhibition of Histone Deacetylase (HDAC) 6 and/or Heat Shock Protein (HSP) 90: A Strategy To Abrogate Multi-Level Protective Responses to Misfolded Proteins Induced by Proteasome Inhibitors in Human Leukemia Cells.
Authors: Rekha Rao, Warren Fiskus, Bryan Herger, Peter Atadja, Kapil Bhalla
Journal: Blood (2006)
P2.03b-058 Blood Cell Count Ratios at Diagnosis as Prognostic Markers in Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Authors: Eliza Ricardo, Bianca Boneti, Taynan Ribeiro, Rafael De Moraes, Helano Freitas, Alexandre Da Costa, Victor Andrade, Vladmir Cordeiro De Lima
Journal: Journal of Thoracic Oncology (2017)
P119 Using adverse events in a tuberculosis trial to describe the tolerability of standard therapy
Authors: CD Tweed, G Wills, AM Crook, SK Meredith, AJ Nunn, CM Mendel, SR Murray, TD McHugh, SH Gillespie
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> The current standard treatment for pulmonary tuberculosis (TB) has been in use for several decades and the major risks associated with each of the four drugs (HRZE) are well recognised. However, large prospective trials with regular review and documentation of adverse events while taking HRZE are lacking. We used the incidence of grade 3 and 4 adverse events (AEs) and serious adverse events (SAEs) in patients taking HRZE in the REMoxTB trial to investigate the overall tolerability of the regimen. <h3>Methods</h3> Grade 3 or 4 AEs and SAEs (of any grade) for patients taking standard TB therapy were analysed. Events were labelled as occurring in the intensive phase, continuation phase or in follow-up (up to 18 months after enrolment). ANOVA and chi-square testing was used to test for significant differences in the incidence of events across the treatment phases. Logistic regression was used to investigate associations between baseline characteristics and on-treatment SAEs and withdrawal from treatment, death or relapse/treatment failure. <h3>Results</h3> 201 (31.5%) of 639 patients taking standard therapy experienced grade 3/4 AEs or SAEs during treatment. AEs, SAEs, and withdrawals from treatment occurred most frequently in the intensive phase (see Table). Of 116 SAEs reported 84 (72.4%) improved or resolved and were most commonly respiratory (16.4%), gastrointestinal (6.9%), and infection (5.2%) related. There were 10 deaths in follow-up due to suicide, trauma, TB relapse, and acute illness. Logistic regression detected a significant association between on-treatment SAEs and withdrawal (p &lt; 0.001) or death (p &lt; 0.001), but not relapse/treatment failure (p = 0.611). HIV-positive status (OR 4.25, p = 0.016) and lower baseline weight (OR 1.46, p = 0.023) were associated with the reporting of on-treatment SAEs. <h3>Discussion</h3> AEs and SAEs were predominantly reported in the intensive phase, probably due to a combination of TB and effects of medication. However most deaths occurred in follow-up and were unrelated, emphasising the impact that social circumstances have on TB patients. The lack of significant association between SAEs during treatment and relapse/treatment failure provides reassurance that a complicated treatment period can end with successful treatment of TB. The association between SAEs on treatment and lower weights at baseline and HIV infection reinforces the need to monitor these patients closely.
Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis
Authors: Marlena Hawro, Marcus Maurer, Karsten Weller, Romuald Maleszka, Anna Zalewska-Janowska, Andrzej Kaszuba, Zofia Gerlicz-Kowalczuk, Tomasz Hawro
Journal: Journal of the American Academy of Dermatology (2017)
Allogeneic Transplantation for Acute Myeloid Leukemia (AML) M2 with Translocation (8;21) and CD56 Positivity Is Effective Even for Patients with Relapsed Disease.
Authors: Tawee Tanvetyanon, Sucha Nand, Amir A. Toor, Tulio E. Rodriguez, Mala Parthasarathy, Patrick J. Stiff
Journal: Blood (2004)
P143 Blood eosinophilia as predictor for patient outcomes in COPD exacerbations: a systematic review and meta-analysis
Authors: RE Villalobos, J Magallanes, A David-Wang
Journal: Thorax (2016)

<h3>Background and significance</h3> COPD exacerbations are associated with significant morbidity, mortality, and substantial healthcare cost. The eosinophilic phenotype of COPD has been demonstrated to respond better to corticosteroids thus providing better clinical outcomes. This review aims to elucidate further the correlation between blood eosinophilia and outcomes in hospitalised patients with COPD exacerbations. <h3>Methods</h3> We systematically searched published and unpublished literature for potential studies that fulfilled our eligibility criteria. Inclusion criteria include any cohort (prospective or retrospective), case-control or randomised trials that looked into the association of blood eosinophilia and outcomes in hospitalised COPD exacerbation patients. The primary study outcome was length of hospitalisation; other outcomes include readmission and mortality rate within 1 year, in-patient mortality, and need for mechanical ventilation. An extensive eligibility, methodological and risk of bias assessments were performed independently by two authors adhering to the MOOSE and Cochrane standards. <h3>Results</h3> Six studies, with a total of 7293 patients, were included in the review. Five are retrospective cohorts and one is a retrospective analysis of a subgroup of a randomised trial. Patients with blood eosinophilia had significantly shorter hospital stay compared to non-eosinophilic patients (mean difference 0.68 days [95% CI: 1.09, 0.27]). Eosinophilic patients had significantly less frequent readmissions (odds ratio/OR 0.69 [95% CI: 0.55, 0.87]) but there was no statistically significant difference in the 1-year mortality rate (OR 0.88 [95% CI: 0.73, 1.06]). Analysis showed a trend toward lower in-patient mortality among eosinophilic patients, although this difference is not statistically significant (OR 0.53 [95% CI: 0.27, 1.05]). Furthermore, COPD patients with eosinophilia had significantly less need for mechanical ventilation during an exacerbation (OR 0.56 [95% CI: 0.35, 0.89]). Only the primary outcome was significantly heterogenous. <h3>Conclusions</h3> COPD patients with blood eosinophilia had significantly shorter hospital stay, less frequent readmissions, and are less likely to require mchanical ventilation compared to the non-eosinophilic phenotype.
Implantation of an Artificial Larynx after Total Laryngectomy
Authors: Christian Debry, N Engin Vrana, Agnès Dupret-Bories
Journal: New England Journal of Medicine (2017)

Organ loss due to late-stage cancer is a heavy burden on both the patient and the health care system. This letter describes a patient who received an artificial larynx to replace lost laryngeal functions and who underwent 16 months of follow-up.
MA04.09 RICTOR Amplification in Non-Small Cell Lung Cancer: An Emerging Therapy Target
Authors: Jeffrey Ross, Haiying Cheng, Roman Perez-Soler, James Suh, Dean Pavlick, Siraj Ali, Alexa Schrock, Julia Elvin, Jo-Anne Vergilio, Shakti Ramkissoon, David Fabrizio, Vincent Miller, Philip Stephens, Laurie Gay
Journal: Journal of Thoracic Oncology (2017)
OA18.07 Quality of Resection and Outcome in Stage III TETs: The French RYTHMIC Network Experience
Authors: Maria Bluthgen, Eric Dansin, Dan Ou, Hervé Léna, Julien Mazieres, Eric Pichon, François Thillays, Gilbert Massard, Xavier Quantin, Youssef Oulkhouir, Thierry Nguyen, Luc Thiberville, Christelle Clément-Duchêne, Colin Lindsay, Pascale Missy, Thierry Molina, Nicolas Girard, Benjamin Besse, Pascal Alexandre Thomas
Journal: Journal of Thoracic Oncology (2017)
P2.02-032 Induction Histology-Based Combination Chemotherapy for Elderly Patients with Inoperable Non-Small Cell Lung Cancer (NSCLC)
Authors: Giuseppe Banna, Giuseppe Anile, Marine Castaing, Ezio Urso, Maurizio Nicolosi, Salvatore Strano, Francesco Marletta, Stefania Calì, Rohit Lal
Journal: Journal of Thoracic Oncology (2017)
P2.01-040 CXC Chemokine Receptor 3 and ELR Motif Negative CXC Chemokine Ligand Axis in Non-Small Cell Lung Cancer
Authors: Artjoms Spaks, Donats Breiva, Ilmars Tracums, Anastasija Bistrova, Krista Grigorovica, Irina Spaka, Inta Jaunalksne, Jurijs Nazarovs
Journal: Journal of Thoracic Oncology (2017)
Gene Therapy of Human Blnk Deficiency in NOD/SCID/Gc Ko Murine Model
Authors: Chantal Lagresle-Peyrou, Michèle Milili, Julien Rouiller, Capucine Picard, Marina Cavazzana-Calvo, Claudine Schiff, Isabelle Andre-Schmutz
Journal: Blood (2011)
P3.03-037 Impact of Sarcomatoid Component in Patients with Biphasic Mesothelioma: Review of 118 Patients
Authors: Andrea Bille, Styliani Maria Kolokotroni, Juliet King, Jeremy Smelt, Leanne Ashrafian, James Spicer, Tom Routledge, Wen Ng
Journal: Journal of Thoracic Oncology (2017)
CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.
Authors: Susann Szmania, Balaji Balasa, Priyangi Malaviarachchi, Fenguhuang Zhan, Yongsheng Huang, Aparna Draksharapu, Vladimir Vexler, John Shaughnessy, Bart Barlogie, Guido Tricot, Daniel Afar, van Rhee Frits
Journal: Blood (2006)
Different Patterns of Cooperating Mutations between De Novo AML Patients with MLL-Partial Tandem Duplication and MLL Translocations.
Authors: Lee-Yung Shih, Der-Cherng Liang, Chein-Fuang Huang, Ya-Tzu Chang, Yu-Shu Shih, Tung-Huei Lin, Huei-Ying Li, Chang-Liang Lai, Tung-Liang Lin, Ming-Chung Kuo
Journal: Blood (2006)
Stem Cell Transplantation from Mismatched Related Donors for Paediatric Haematological Disorders : The Hospital for Sick Children, Toronto, Experience.
Authors: Gary Nicolin, Prabodh Das, Elizabeth McDougall, Adam Gassas, Lillian Sung, Wendy Lau, E. Fred Saunders, John Doyle, Stan Calderwood
Journal: Blood (2004)
P2.01-017 Circulating miRNAs in Lung Cancer Are Associated to Pro-Tumorigenic and Immunosuppressive Microenvironment
Authors: Orazio Fortunato, Cristina Borzi, Giovanni Centonze, Massimo Milione, Davide Conte, Mattia Boeri, Carla Verri, Linda Calzolari, Francesca Andriani, Luca Roz, Veronica Huber, Agata Cova, Chiara Camisaschi, Chiara Castelli, Licia Rivoltini, Claudio Tripodo, Ugo Pastorino, Gabriella Sozzi
Journal: Journal of Thoracic Oncology (2017)
P2.06-023 A Phase III Study Comparing Gefitinib and Inserted Cisplatin plus Pemetrexed with Gefitinib for EGFR-Mutated Advanced Non-Squamous NSCLC
Authors: Shintaro Kanda, Tomonori Mizutani, Taro Shibata, Seiji Niho, Takayasu Kurata, Shinichiro Nakamura, Nobuyuki Yamamoto, Yuichiro Ohe
Journal: Journal of Thoracic Oncology (2017)
P1.03-015 Assessment of Response of FDG-PET Using Total Lesion Glycolysis (TLG) in NSCLC Patients Treated with Nivolumab: Results of a Pilot Study
Authors: Giulia Fichera, Marco Aiello, Laura Noto, Nunzio Restuccia, Massimo Ippolito, Hector Soto Parra
Journal: Journal of Thoracic Oncology (2017)